Nature biotechnology
The most recent articles from:
Nat. Biotechnol.
-
Industry has been warned: US Food and Drug Administration (FDA) approval is no shield against failure-to-warn or product-liability suits.
-
The thinking behind the US Food and Drug Administration's (FDA) draft guidance on financial conflicts of interest for outside experts is deeply flawed.
-
Is biological research ready for the new wave of data-reporting standards currently under development?